Development of a treatment algorithm for kinase inhibitor therapy in CML.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1027560

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chronic myeloid leukaemia has become a highly treatable condition since targeted therapy became available. There are now 3 highly effective drugs available, imatinib, nilotinib and dasatinib. We are developing drug sensitivity assays that can be used to predict response to these 3 drugs. We propose that these assays could be used to individualise therapy to ensure that the optimal drug can be provided for each patient from diagnosis to provide a cost-effective customized approach to therapy.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $527,761.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chronic myeloid leukaemia (CML) | drug efficacy | drug resistance | kinase inhibitors | treatment strategies

Related Links